U.S. Energy Services Stock News

RadNet (NasdaqGM:RDNT) announced plans to acquire AI medical imaging firm Gleamer for nearly US$270 million. The deal has sparked debate among investors over the price tag and strategic fit of the AI-focused expansion. A short-seller report has also questioned RadNet's accounting methodology and use of certain key performance metrics. RadNet operates a large outpatient imaging network, so adding Gleamer's AI tools would plug directly into its core business of radiology services. The move...

New England Realty Associates Limited Partnership (NEN) closed out FY 2025 with Q4 revenue of US$22.6 million and a basic EPS loss of US$0.40, while trailing 12 month EPS stood at US$1.72 on revenue of US$89.2 million. The partnership has seen revenue in recent quarters move from US$20.8 million in Q4 2024 to between roughly US$21.1 million and US$23.8 million across FY 2025, with quarterly EPS ranging from earnings of US$1.20 to a loss of US$0.40. This sets up a mixed margin picture that...

Hotel Indigo Panama City Marina, a property developed by The St. Joe Company (NYSE:JOE), received IHG Hotels & Resorts' top Torchbearer Award for guest experience excellence. The Torchbearer Award recognizes hotels within the IHG system that achieve leading guest satisfaction scores and operational performance. This recognition puts a spotlight on St. Joe's hospitality operations at a time when coastal leisure travel and branded hotel experiences remain a key focus for many real estate...

If you are wondering whether Alphabet shares still offer value at today's price, it helps to step back and look at what the current market is really pricing in. The stock most recently closed at US$302.28, with returns of 1.3% over 7 days, a 2.8% decline over 30 days, a 4.1% decline year to date, and an 83.3% return over the past year, alongside returns of 199.9% over 3 years and 200.7% over 5 years. Recent coverage of Alphabet has focused on its position as a major global technology and...

In the past week, Ingersoll Rand reported stronger-than-expected fourth-quarter 2025 results and completed the acquisition of Scinomix, Inc. to expand its life sciences automation capabilities. Yet these operational positives coincided with declining organic revenue, execution concerns, and insider selling, highlighting a tension between growth ambitions and investor confidence. We’ll now examine how the stronger-than-expected earnings, alongside the Scinomix acquisition, might reshape...

Essent Group (ESNT) shares are in focus after the mortgage insurer reported flat year on year revenue of US$312.4 million that met expectations, while earnings came in below consensus estimates, shifting attention toward profitability. See our latest analysis for Essent Group. The mixed earnings reaction comes after a softer patch for the share price, with a 30 day share price return of 11.33% and a year to date share price return of a 10.17% decline. Meanwhile, the 1 year total shareholder...

Sesame Workshop has filed a lawsuit against United Parks & Resorts (NYSE:PRKS), alleging unpaid royalties and contractual breaches tied to Sesame Place attractions. The suit seeks to terminate the long running licensing agreement and obtain damages related to the use of the Sesame Street brand in United Parks & Resorts themed entertainment portfolio. The dispute centers on the Sesame Place branded parks, which rely on access to Sesame Workshop intellectual property and characters for their...

Mid-America Apartment Communities (MAA) has been drawing attention after recent share price pressure, with the stock showing negative returns over the past month, past 3 months and year. That slump is prompting closer scrutiny from income-focused REIT investors. See our latest analysis for Mid-America Apartment Communities. The latest share price of US$126.32 leaves Mid-America Apartment Communities with a 7-day share price return of a 4.9% decline and a year-to-date share price return of a...

Earlier this month, Vericel Corporation received U.S. FDA approval to begin commercial manufacturing of its MACI cartilage repair therapy at its new Burlington, Massachusetts cell therapy facility starting in the second quarter of 2026, expanding capacity for symptomatic knee cartilage defect treatment in adults. This manufacturing approval not only supports higher MACI production volumes but also strengthens Vericel’s ability to pursue potential commercialization of the therapy in markets...

Halcyon has integrated its technology with Freddie Mac's Asset and Income Modeler (AIM) to support automated dual source income assessment for self employed borrowers. The solution combines borrower provided tax returns with IRS transcripts, automating data validation for lenders using Freddie Mac loans. The capability is immediately available to approved lenders, allowing faster adoption in current mortgage underwriting workflows. For investors watching Federal Home Loan Mortgage...

If you are trying to work out whether Ocular Therapeutix at around US$8.76 is a bargain or just fairly priced, starting with a clear view of its valuation can help frame your next move. The stock has seen mixed returns, with a 14.7% decline over the last 7 days and a 4.4% decline over the last 30 days, while the 1 year return sits at 13.5% and the 3 year return at 76.6%, compared with a 57.6% decline over 5 years. Recent market attention on Ocular Therapeutix has focused on its progress as...

How BioMarin Pharmaceutical’s Recent Moves Set Up a Closer Look at Value Before we get into the numbers, if you are wondering whether BioMarin Pharmaceutical’s current share price fairly reflects its long term potential, it helps to first step back and see what the market has been doing with the stock lately. BioMarin’s share price closed at US$58.51 most recently, with returns of 4.3% decline over the past week, 3.0% decline over the past month, a 1.6% decline year to date, and a 15.7%...

Edgewise Therapeutics recently presented long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy at the 2026 MDA Clinical and Scientific Conference, showing multi-year stabilization of patient function and a favorable safety profile in a disease with no approved therapies. An unusually high 99% of eligible participants from earlier sevasemten trials chose to continue into the MESA extension, underscoring sustained engagement with the investigational...

If you are wondering whether Veralto, at around US$90.20, is offering fair value right now or if the market is mispricing it, this article walks you through what the numbers actually say. The stock has recently been under pressure, with a 7 day return of a 4.4% decline, a 30 day return of a 5.1% decline and a year to date return of an 8.4% decline, adding to a 1 year return of a 7.5% decline. Recent coverage around Veralto has focused on how the newly listed business fits into the broader...

If you are wondering whether Terex shares are still offering value at current levels, you are not alone. This article will walk through what the market price might be implying about the business. The stock last closed at US$59.41, with returns of 8.0% year to date and 49.4% over the past year. However, a 4.3% decline over the last week and a 14.0% decline over the last month shows sentiment has recently cooled. These short term moves sit against a longer backdrop where Terex has also...

Exelixis recently reported quarterly adjusted earnings per share that exceeded expectations, helped by higher Cabometyx volumes and lower operating expenses, while the FDA accepted its New Drug Application for zanzalintinib in metastatic colorectal cancer with a target action date in December 2026. Alongside these results, the company reiterated its 2026 guidance and benefited from multiple upward analyst earnings estimate revisions, underscoring how regulatory milestones and disciplined...

CRH plans to delist its ordinary and preference shares from the London Stock Exchange, subject to shareholder approval. If approved, the company will maintain a sole primary listing on the New York Stock Exchange under the ticker NYSE:CRH. The move is intended to consolidate trading in one market and could affect how different groups of investors access and trade the shares. NYSE:CRH currently trades at $99.82, with the share price showing a 4.1% gain over the past year and a 132.7% return...

NGL Energy Partners LP recently closed a seven-year US$950 million senior secured term loan facility and amended its asset-based revolving credit facility, using the proceeds to repay existing borrowings, repurchase a portion of its Class D Preferred Units, and for general corporate purposes. This refinancing reshapes the partnership’s mix of debt and preferred equity, with the targeted repurchase of about 195,000 Class D units signaling a push for a simpler, more flexible capital...

If you are wondering whether Teradata's current share price offers good value or not, you are in the right place because this article focuses squarely on what the numbers say about the stock. Teradata shares last closed at US$26.58, with a 7 day return of a 5.1% decline, a 30 day return of a 29.8% decline, and a 1 year return of a 17.1% gain, which gives you a sense of both recent setbacks and longer term recovery. Recent attention on Teradata has been shaped by ongoing interest in data and...

FIGS (NYSE:FIGS) is partnering with US lawmakers on the Healthcare is Human Act, a bipartisan federal bill. The proposed legislation would offer tax credits to healthcare professionals working in shortage areas. The effort is aimed at addressing workforce shortages and burnout in critical healthcare settings. FIGS, best known for its premium medical scrubs and apparel, is closely tied to the everyday realities of healthcare workers. By stepping into the policy arena through the Healthcare...

If you are wondering whether Ulta Beauty's share price still makes sense after its recent swings, this article will walk through what the current market tag might be telling you about the stock's value. The shares most recently closed at US$535.72, after a 17.1% decline over the last 7 days and a 21.6% decline over the last 30 days, set against a 49.9% return over the past year. Recent price moves have come alongside ongoing attention on Ulta Beauty's position in the US specialty retail...

Wondering if Symbotic at around US$49.43 is still a compelling opportunity or already pricing in a lot of optimism? This article is going to focus squarely on what the current share price implies about the company’s value. Over the past week the stock returned 1.7%, while the 30 day return was a 15.4% decline and the year to date return was a 23.8% decline, set against a 128.3% return over the last year and 164.0% over three years. Recent coverage around Symbotic has largely focused on its...

If you are wondering whether WSFS Financial at around US$62.72 is still offering value or starting to look fully priced, you are not alone. The stock has had a mixed run recently, with a 0.4% decline over the last 7 days and a 7.3% decline over 30 days, set against stronger returns of 13.9% year to date, 22.1% over 1 year, 68.9% over 3 years and 28.5% over 5 years. Recent coverage has focused on the bank's positioning in its regional markets and how investors are weighing those fundamentals...

Antero Midstream (NYSE:AM) has completed a US$1.1b acquisition of Marcellus midstream assets. The transaction expands the company’s midstream footprint and capacity in a key U.S. natural gas region. Management expects 2026 adjusted EBITDA and free cash flow after dividends to be 8% and 11% higher, respectively, versus prior expectations. The business continues to operate under fixed-fee, take-or-pay contracts that reduce direct exposure to commodity price swings. For you as an investor,...